Larimar Therapeutics Inc Stock

$2.95

1.03% today

Nasdaq, Feb 28, 04:48 pm CET

ISIN

US5171251003

Symbol

LRMR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Services

Industry

Various services

Overview Dividends Analysts Charts News Strategies

Larimar Therapeutics Inc Stock price

$2.92

-10.16 77.68% 5Y

Nasdaq, Closing price Thu, Feb 27 2025

-0.01 0.34%

ISIN

US5171251003

Symbol

LRMR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Services

Industry

Various services

Key metrics

Market capitalization	$186.32m
Enterprise Value	$-12.03m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	0.20
P/B ratio (TTM) P/B ratio	0.94
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-73.76m
Free Cash Flow (TTM) Free Cash Flow	$-58.79m
Cash position	$203.71m
EPS (TTM) EPS	$-1.15
P/E forward	negative
Short interest	12.17%

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Get Started for Free Today

Larimar Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

12 Analysts have issued a Larimar Therapeutics Inc forecast:

12x Buy

100%

More details on Analyst Estimates Including Price Targets

12 Analysts have issued a Larimar Therapeutics Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Larimar Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.32 0.32	60% 60% -
Gross Profit	-0.32 -0.32	60% 60% -
- Selling and Administrative Expenses	16 16	20% 20% -
- Research and Development Expense	57 57	137% 137% -
EBITDA	-73 -73	94% 94% -
- Depreciation and Amortization	0.32 0.32	60% 60% -
EBIT (Operating Income) EBIT	-74 -74	94% 94% -
Net Profit	-65 -65	94% 94% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Larimar Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

about one month ago

Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia

BALA CYNWYD, Pa., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that dosing of adolescents 12-17 years old has started in the Company's pediatric PK run-in study for patients with Friedreich's ataxia (FA).

Positive

Seeking Alpha

●

about 2 months ago

Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better

Larimar Therapeutics, Inc. reported initial positive data from phase 2 long-term OLE study using nomlabofusp for treatment of patients with Friedreich's Ataxia; Increase of tissue FXN protein levels from 15% to 30%. The global Friedreich's Ataxia market size is projected to reach $2.06 billion by 2030. Additional data using higher 50 mg dose of nomlabofusp to treat patients with Friedreich's At...

Neutral

GlobeNewsWire

●

2 months ago

Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia

BALA CYNWYD, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced positive initial data from the ongoing long-term OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver in ...

More Larimar Therapeutics Inc News

Company Profile

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead compound, CTI-1601, is being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease. It also focuses on using its intracellular platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. The company is headquartered in Bala Cynwyd, Pennsylvania.

Head office	United States
CEO	Carole Ben-Maimon
Employees	42
Founded	2005
Website	larimartx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now